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Objective: To assess the evidence regarding the differences in areal bone mineral density 
(aBMD) between children and adolescents with cystic fibrosis (CF) compared with their 
healthy peers, based on data from longitudinal studies. Study design: We searched 
MEDLINE, SPORTDiscus, the Cochrane Library, PEDro (Physiotherapy Evidence 
Database), and Embase databases. Observational studies addressing the change of aBMD 
in children with CF and healthy children and adolescents were eligible. The DerSimonian 
and Laird method was used to compute pooled estimates of effect sizes (ES) and 95% CIs 
for the change of whole body (WB), lumbar spine (LS), and femoral neck (FN) aBMD. 
Results: Six studies with participants with CF and 26 studies with healthy participants 
were included in the systematic review and meta-analysis. For the analysis in children 
with CF, the pooled ES for the change of WB aBMD was 0.29 (95% CI –0.15 to 0.74), 
for the change of LS aBMD was 0.13 (95% CI –0.16 to 0.41), and for the change of FN 
aBMD was 0.09 (95% CI –0.39 to 0.57). For the analysis in healthy children, the pooled 
ES for the change of WB aBMD was 0.37 (95% CI 0.26-0.49), for the change of LS 
aBMD was 0.13 (95%CI –0.16 to 0.41), and for the change of FN aBMD was 0.52 (95% 
CI 0.19-0.85). Conclusions: aBMD development might not differ between children and 
adolescents with CF receiving medical care compared with their healthy peers. Further 
longitudinal studies in a CF population during growth and development are required to 
confirm our findings. 
 Introduction 
Cystic fibrosis (CF) is an inherited disease affecting the correct functioning of numerous 
vital organs, such as the lungs and the gastrointestinal tract (1). It is caused by mutations 
in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene and it is the 
most prevalent (autosomal recessive) disorder in the Caucasian-race population. The 
median age at death, 29.1 years, has continuously increased over the last two decades, 
and nowadays more than half of the individuals with CF are 18 years or older (2), 
suggesting an increase in the likelihood of having long-term CF sequels. These include 
low areal bone mineral density (aBMD), osteoporosis-related fractures and abnormal 
excessive convex curvature of the spine (e.g. kyphosis) (3-5), which in turn may cause 
pain when breathing and impair physical activity levels, which can contribute to bone 
accrual (6). CF is also related to exocrine pancreatic insufficiency, characterised by a 
deficiency in the number of exocrine pancreatic enzymes and causing an inability to 
digest food and absorb nutrients, which affects proper development in children and 
adolescents with CF (1, 7). In this regard, a poor nutritional status has been associated 
with a reduction in lung function, impaired pulmonary muscle function, and tolerance 
levels towards exercise (8).  
 
Multiple factors seem to explain the link between low aBMD and CF, including poor 
nutritional status, nutrient malabsorption and clinical status (9-12) but also a more direct 
pathway through the CFTR gene mutation, which may lower aBMD (11). The association 
between aBMD and CF may vary depending on whether it is looked at in growing or 
adult population. Findings from a systematic review and meta-analysis showed that 38% 
and 23.5% of the adults with CF had osteopenia and osteoporosis, respectively (13). It is 
known that bone acquisition occurs throughout childhood and adolescence, with 80-90 % 
acquired by late adolescence, depending of the sites of the skeleton (14, 15). Therefore, 
the origins of bone disease in CF are likely to occur during childhood or adolescence.  
 
The scientific evidence regarding bone mineralization in CF is controversial (4, 16-20). 
Some evidence points out the prevalence of low aBMD in children and adolescents (21-
23), and suggest lung function and nutritional status as important determinants of low 
aBMD in CF (16, 23-25). The study of Reix, Bellon (26) showed that bone alterations 
may be already present in children younger than 6 years of age, and highlighted that 
monitoring bone status in this population is needed. In contrast, other studies highlight a 
minimal difference in bone mass in CF (relative to normal) but that this difference is more 
important at later life stages, such as adulthood (27-29). In this regard, the CF Foundation 
consensus statement on bone health and disease recommends monitoring CF adults with 
Dual energy X-ray Absorptiometry (DXA) and subsequent follow-up based on the 
findings (2). 
 
DXA is considered the gold standard method for assessing aBMD and has been used 
worldwide not only in adults but also in children and adolescents (30). In a clinical setting, 
the most common sites measured with DXA are the lumbar spine, hip (total hip or 
proximal femur), and total body (31, 32). Considering the increase in life expectancy in 
people with CF and associated sequels, such as the increased risk of osteoporosis, 
examining whether low bone mass is already apparent in children and adolescents with 
CF must be viewed as a high priority. To the best of our knowledge, no meta-analysis has 
analysed whether aBMD differs between CF and healthy children and adolescents.   
 
Therefore, this systematic review and meta-analysis aims to examine the differences in 
aBMD between children and adolescents with CF compared to their healthy peers based 
on data from longitudinal studies. 
 
Methods  
This study was reported according to the Meta-analysis of Observational Studies in 
Epidemiology statements (MOOSE) (33) and followed the recommendations of the 
Cochrane Collaboration Handbook (34). This systematic review and meta-analysis was 
registered through the International Prospective Register of Systematic Reviews 
(Registration number: CRD42018099671). 
 
Search strategy 
We systematically searched MEDLINE (via PubMed), SPORTDiscus, the Cochrane 
Library, PEDro (Physiotherapy Evidence Database) and Scopus (via databases from their 
inception until October, 2018). Observational studies addressing the change of aBMD in 
both, cystic fibrosis and healthy, across the childhood and adolescence period were 
eligible. The search strategy included the following terms for cystic fibrosis populations: 
(bone) AND (children OR adolescents OR young OR boys OR girls) AND (“cystic 
fibrosis”); and for healthy populations: (bone) AND (children OR adolescents OR young 
OR boys OR girls) AND (healthy). The literature search was complemented by reviewing 
citations of the articles considered eligible for the systematic review and authors were 
contacted to obtain missing information when necessary. 
 
Study selection  
The criteria for including studies were as follows: i) participants: cystic fibrosis 
population samples or healthy population samples; ii) study design: longitudinal studies, 
with prospective data collection; iii) exposure: bone development during the follow-up; 
and iv) outcome: aBMD. The criteria for excluding studies were as follows: i) reports not 
written in English or Spanish; ii) studies including individuals aged below 18 years old; 
and iii) non-eligible publication types, such as review articles, editorials, comments, 
guidelines or case-reports. 
 
When more than one study provided data from the same sample, we only considered the 
one presenting the most detailed results or providing data for the largest sample size. 
However, data regarding sample characteristics could be extracted from multiple reports 
to obtain the most complete information 
 
The literature search was independently conducted by two reviewers (EUG and LGM), 
and disagreements were solved by consensus or involving a third researcher (ICR). 
 
Data extraction and quality assessment  
The following data were extracted from the original reports (1) first author and year of 
publication, (2) country of the study where data were collected, (3) length of follow-up, 
(4) sample characteristics (age, sample size, BMI, stature, weight and type of population) 
and, (5) bone measurement characteristics (aBMD measurement method used, values for 
each aBMD [WB, LS and FN] at baseline and at end of follow-up). 
Quality Assessment tool for Observational Cohort and Cross-sectional Studies from the 
National Heart, Lung and Blood Institute (35) was used to evaluate risk of bias for cohort 
and cross-sectional studies. Assessed methodological criteria included: research question, 
population definition, participation rate, recruitment, sample size, analysis, timeframe, 
exposure levels, measures and assessment, outcome measures and blinding, loss at follow 
up and confounding variables. Each study was rated either as good (i.e., most criteria met, 
and with a low risk of bias), fair (i.e., some criteria met, with a moderate risk of bias), or 
poor (i.e., few criteria met, and with a high risk of bias). 
 
Data extraction and quality assessment were independently performed by two researchers 
(EUG and LGM), and inconsistencies were solved by consensus or involving a third 
researcher (ICR). 
 
Statistical analysis and data synthesis 
The inverse-variance fixed effects method (36), were used to compute pooled estimates 
of effect size (ES) and respective 95% CI. When the studies presented aBMD mean values 
for baseline and end-point or aBMD mean value change, effect size (ES) were calculated. 
ES values around 0.2 were considered to be a weak effect, values around 0.5 were a 
moderate effect, values around 0.8 were a strong effect, and values larger than 1.0 were 
a very strong effect. In order to compare the differences in aBMD changes between cystic 
fibrosis and healthy population the meta-analysis was done separately. The heterogeneity 
of results across studies was assessed using the I2 statistic (37). I2 values are considered 
as: might not be important (0% to 40%), may represent moderate heterogeneity (30% to 
60%), substantial heterogeneity (50% to 90%) or considerable heterogeneity (75% to 
100%); the corresponding p-values were also taken into account (34). 
 
Sensitivity analyses (systematic re-analysis while removing studies one at a time), and 
subgroup analyses were conducted in order to assess the robustness of the summary 
estimates. Results of the sensitivity analyses were considered meaningful when the 
resulting estimates were modified beyond the confidence intervals of the original 
summary estimate. In addition, sensitivity analyses provided insight as to whether any 
particular study or subgroup accounted for a large proportion of heterogeneity among the 
correlation pooled estimations, based on the change in I2 values (and associated categories 
previously reported). 
Random-effects meta-regression analyses were performed to determine whether age and 
length of follow-up to examine their interaction effect on the aBMD change comparing 
healthy and cystic fibrosis populations. Finally, to assess publication bias, Egger’s 
regression asymmetry test was used (38). A level of <0.10 was used to determine if 
publication bias might be present. Statistical analyses were performed using StataSE 
software, version 14 (StataCorp). 
Results 
Systematic Review 
We identified 6 longitudinal studies (Table 1) (21, 39-43) about the development of 
aBMD in children and adolescents with cystic fibrosis. In parallel, we identified 29 
studies (Table 2) (44-72) with longitudinal data of aBMD in healthy children and 
adolescents. The compilation of these studies allow us to compare the status of bone 
health in cystic fibrosis young with a healthy peers (control studies) over the time. 
 
Regarding to the cystic fibrosis studies, these were carried out in 4 different countries: 
three from USA, one from Italy, one from New Zealand and one from Hungary. Reports 
were published between 1998 and 2017, and they included longitudinal studies using the 
following designs: five were follow-up non-randomised studies and one was a 
randomised trial. Length of studies ranged from 9 months to 5 years. 
 
All the participants suffered cystic fibrosis and one of the study the participants 
underwent liver transplantation. Included participants were aged between 4 and 18 years, 
with sample sizes ranging from 9 to 40 subjects. Concerning assessment methods carried 
out in the studies, all of them used a dual-energy x-ray absorptiometry scanner to measure 
bone outcomes: two studies used the model Hologic 1000W, one study used the model 
Hologic QDR 2000, two studies used the model Hologic QDR-4500, and one study used 
the model Lunar Prodigy. 
 
Regarding to the control studies, these were realised in 12 different countries: one from 
Brazil, two from Spain, three from Switzerland, five from Australia, four from Canada, 
seven from USA, one from United Kingdom, one from Estonia, one from France, two 
from Sweden, one from Belgium and one from Denmark. Data were published between 
1991 and 2017 and they included longitudinal studies using the following designs: twelve 
were follow-up non-randomised studies and seventeen were randomised-controlled trial. 
Length of studies ranged from 3 months to 14 years. 
 
All the participants were healthy children and adolescents. The range age of the 
participants was 4 to 18 years, with sample sizes between 9 to 124. Concerning 
assessment methods carried out in the studies, all of them used a dual-energy x-ray 
absorptiometry scanner to measure bone outcomes: eight studies used the model Lunar 
Prodigy, one study used the model Hologic QDR 1500, three studies used the model 
Hologic QDR 2000, five studies used the model Hologic QDR 1000W, ten studies used 
the model Hologic QDR 4500, one study used the model Hologic WB Delphi, and one 
study used the model Norland Medical XR800. 
 
Study Quality 
The risk of bias was evaluated by a quality assessment tool for observational cohort and 
cross-sectional studies for The National Institutes of Health (73). The cystic fibrosis 
studies showed a 33.3% of high risk of bias and 66.7% of moderate risk of bias. The 
control studies showed a 51.7 % of high risk of bias, a 44.8% of moderate risk of bias, 
and a 3.4% of low risk of bias. 
 
When studies were analysed by individual domains, 100% of the cystic fibrosis studies 
defined a clearly research question, took into account the exposure(s) of interest measured 
prior to the outcome(s) being measured, the timeframe was sufficient, the exposure 
measures (independent and dependent variables) were clearly defined, valid, reliable, and 
implemented consistently, and presented a lower percentage of 20% of withdrawals/drop-
outs. However, no study or just one had presented a sample size justification (power 
description, or variance and effect estimates) and had shortcomings in the blinding 
domain. On the other hand, approximately 100% of the control studies defined a clearly 
research question, the timeframe was sufficient, and the exposure measures (independent 
and dependent variables) were clearly defined, valid, reliable, and implemented 
consistently. However, less than 25% had presented a sample size justification (power 
description, or variance and effect estimates) and have shortcomings in the blinding 
domain. 
 (Electronic Supplementary Material Tables S2 and S3). 
Meta-analysis 
To more clearly display the pooled ES estimates of WB, LS, and FN aBMD, we have 
provided forest plots including the pooled ES estimates, their 95% CI and the I2 
heterogeneity statistic for healthy and cystic fibrosis children (Figures 2-4).  
 
WB aBMD 
Finally, for the analysis in cystic fibrosis children, the pooled ES for the change of WB 
aBMD was 0.29 (95% CI -0.15–0.74), with no heterogeneity (I2 = 0.0%; p = 0.829). 
Furthermore, for the analysis in healthy children, the pooled ES for this change was 0.25 
(95% CI 0.13–0.37), with not important heterogeneity (I2 = 35.8%; p = 0.071) (Figure 2). 
 
LS aBMD 
Additionally, regarding the change of LS aBMD, the pooled ES in cystic fibrosis children 
was 0.13 (95% CI -0.16–0.41), with no heterogeneity (I2 = 0.0%; p = 1.000). Besides in 
healthy children the pooled ES was 0.29 (95% CI 0.18–0.40), with not important 
heterogeneity (I2 = 21.0%; p = 0.209) (Figure 3). 
 
FN aBMD 
For the analysis in cystic fibrosis children, the pooled ES for the change of FN aBMD 
was 0.09 (95% CI -0.39–0.57), with no heterogeneity (I2 = 0.0%; p = 0.999). Furthermore, 
for the analysis in healthy children, the pooled ES for this change was 0.20 (95% CI 0.11–
0.30), also with no heterogeneity (I2 = 0.0%; p = 0.558) (Figure 4). 
 
 
Sensitivity analysis, meta-regression subgroup analysis and publication bias 
The pooled ES estimate was not significantly modified in magnitude or direction when 
individual study data were removed from the analysis one at a time. 
 
The random-effects meta-regression model showed that length of follow up, age, BMI, 
height and weight were not related to FN, LS or WB aBMD change across studies either 
for cystic fibrosis children or for healthy children (Figures XXX-XXX in the 
Supplementary file). 
 
Finally, evidence of publication bias was found by funnel plot asymmetry and Egger’s 
test for the change of LS aBMD in cystic fibrosis children (p = 0.027) and for the change 
of WB aBMD in healthy children (p = 0.073) (Figures XXX-XXX in the Supplementary 
file). 
 
Discussion 
In the present systematic review and meta-analysis, children and adolescents affected by 
CF did not present lower aBMD compared with their peers without CF. To the best of 
our knowledge, this is the first meta-analysis analysing the status of aBMD in CF children 
and adolescents.  
 
Among other factors, a poor nutritional status, nutrient malabsorption and clinical status 
have been suggested in previous investigations as determinants that may explain the 
association between low aBMD and CF (9-12). However, there is controversial in the 
scientific literature on whether CF patients present poorer bone mineralization (4, 16-20). 
Our data show that longitudinal changes in WB, LS and FN aBMD in children and 
adolescents with CF are not different from those found in their healthy peers. These 
results are in accordance with the cross-sectional study by Buntain, Greer (10) in which 
it was found that well-nourished prepubertal children with CF had no significant 
differences in WB, LS and FN aBMD than a healthy control group. Young adults with 
CF have shown a low bone turnover with reduced bone formation but there is no evidence 
for increased bone resorption (74, 75). Nevertheless, it seems that the prevalence of CF-
related bone disease increases with age (19, 76). For example, <5% of children with CF 
presented bone disease, increasing to 20% in adolescents and 55 to 65% in adults older 
than 45 years (29). Therefore, deficits in aBMD seem to be more evident in adulthood 
than childhood (10). 
 
In contrast to our findings, previous investigations have shown bone disease in CF youth 
patients (16, 21-23, 26). Schulze, Cutchins (41) found that low bone mass was usual 
among their cohort of adolescent girls with CF, and approximately a 40% of the girls 
presented deficits in expected bone mineral content at the lumbar spine, and above 20% 
in expected bone mineral content at the WB. In this line, a longitudinal study indicated 
failure to gain bone at the expected rate in youths (21).  
 
These findings can be extrapolated to the adult population, since it has been demonstrated 
through anterior research that adults with CF present bone disease (16, 21, 23, 24). In a 
systematic review and meta-analysis in young adults with CF, the prevalence of 
osteoporosis was 23.5%, the prevalence of osteopenia was 38.0%, and the prevalence of 
vertebral and non-vertebral fractures were 14.0% and 19.7%, respectively (13). In this 
sense, a longitudinal study showed inadequate values of aBMD in adults (21). 
These discrepancies and the fact that our meta-analyses did not show differences in 
aBMD between groups may in part reflect our sample characteristics since participants 
with CF remained on their standard meds as part of their usual treatment regimen, which 
included daily multivitamin and mineral supplements as ADEK vitamins, calcium 
supplementation, and use of pancreatic enzyme supplements, mainly (40-43). In addition, 
our sample of healthy participants were mostly physically inactive (44, 45, 49, 51, 55, 
57-59, 61, 64, 65, 67, 72) and/or did not meet the minimum calcium and/or vitamin D 
intake (46, 47, 52-54, 59, 66, 68). It is known that nutritional status is a major determinant 
of aBMD (42), importantly vitamin D and K deficiencies, and a negative calcium balance 
(27). In other words, CF children who receive the nutritional supplementation as part of 
their medical treatment do not have their aBMD negatively affected. Similarly, young 
people with CF has affected bone accrual in those with the poorest nutritional status (42). 
So, aBMD is usually normal in children with CF with no nutritional deficit (20), which is 
the case in 4 out of 6 studies (40-43), omitting that information in the other 2 studies (21, 
39). Further, it has been demonstrated that calcium absorption is normal in children with 
CF (40) and that those who have never received steroid treatment could also present bone 
deficit (43). So, steroid treatment is not determinant in the development of bone deficit 
(43). In 4 out of 6 studies (21, 39, 41, 42), some of the patients received steroid treatment 
while in the other two studies they did not receive (40, 43) 
 
We must also bear in mind that they are children and, therefore, they are growing. The 
greatest growth and skeletal maturation occurs at the end of puberty when ~51% of the 
peak bone mass is attained (77). In this regard, it has been demonstrated that total body 
bone mineral content increases across pubertal groups, as a consequence of pubertal 
growth (41). Therefore, it is important to optimize bone health in children, adolescents 
and adults with CF through strategies that include a nutritional plan, vitamin K, vitamin 
D and calcium supplementation if necessary, and as well as weight bearing exercise (27). 
Exercise during childhood, especially high impact sports (such as football, handball or 
basketball) have been related to improvements in aBMD (78, 79), and strength at loaded 
sites (80). Additionally, it is recommended to monitor patients with CF through DXA 
scanners to have a follow-up of their bone health according to the European Cystic 
Fibrosis Society (81). 
 
Some limitations need to be acknowledged. First, the limited number of published studies 
investigating bone health in children and/or adolescence with CF must be taken into 
account. For this reason, confidence intervals are large compared to the studies in healthy 
children and adolescents. Second, data extraction were non-blinded, which is a potential 
source of bias. Third, 66.7% of the CF studies and a 44.8% of the healthy studies 
presented moderate risk of bias. Fourth, the use of covariates in the studies was 
heterogeneous, although we have always tried to analyse raw data. Finally, the majority 
of the studies did not present a sample size justification, and had shortcomings in the 
blinding domain. 
 
In conclusion, our meta-analysis showed that aBMD values do not differ between well-
nourished children and adolescents with CF and those from their healthy peers. This 
underlines that in spite of the problems associated with this disease, correct 
supplementation strategies and clinical care may counteract the possible detrimental 
consequences of CF on bone health during growth. In addition, long-term physical 
activity programs may further protect against the sequels of CF on bone mass.  
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Table 1. Characteristics of studies included in the systematic review and meta-analysis in cystic fibrosis participants. 
Study (year) Country Study design 
Population characteristics at baseline Outcome 
Age 
[years (mean 
± SD)] 
Sample size 
[n (% male)] 
BMI 
[kg/m2 (mean 
± SD)] 
Stature 
[cm (mean 
± SD)] 
Weight 
[kg (mean  
± SD)] 
Type of 
population 
Method Baseline bone Follow-up bone 
Bhudhikanok 
et al. (1998) 
USA 
Longitudinal 
study 
(1.5 years) 
Males 
11.8 ± 2.7 
 
Females 
12.1 ± 2.7 
20 (45%) 
Males 
18.5 ± 3.0 
 
Females 
16.2 ± 2.3 
Males 
146 ± 18 
 
Females 
145 ± 15 
Males 
41.0 ± 16.4 
 
Females 
35.1 ± 11.2 
Patients with 
cystic fibrosis 
Hologic QDR 
1000W dual-
energy x-ray 
absorptiometry 
scanner (Hologic 
Corporation, 
Waltham, Mass) 
Males 
(mean ± SD): 
WB BMD (g/cm2): 
0.855 ± 0.106 
LS BMD (g/cm2): 
0.661 ± 0.140 
FN BMD (g/cm2): 
0.706 ± 0.114 
 
Females 
(mean ± SD): 
WB BMD (g/cm2): 
0.815 ± 0.133 
LS BMD (g/cm2): 
0.704 ± 0.210 
FN BMD (g/cm2): 
0.616 ± 0.146 
Males 
(mean ± SD): 
WB BMD (g/cm2): 
0.864 ± 0.103 
LS BMD (g/cm2): 
0.678 ± 0.116 
FN BMD (g/cm2): 
0.718 ± 0.113 
 
Females 
(mean ± SD): 
WB BMD (g/cm2): 
0.829 ± 0.144 
LS BMD (g/cm2): 
0.731 ± 0.227 
FN BMD (g/cm2): 
0.637 ± 0.182 
Colombo et 
al. (2005) 
Italy 
Longitudinal 
study 
(5 years) 
11.5 ± 1.6 4 (75%) 16.9 ± 2.1 142.0 ± 5.0 34.0 ± 4.0 
Liver transplant 
patients with 
cystic fibrosis 
Hologic QDR 
2000 dual-energy 
x-ray 
absorptiometry 
scanner (Hologic 
Inc., Bedford, 
MA, USA). 
(Mean ± SD): 
WB BMD (g/cm2): 
0.810 ± 0.122 
 
(Mean ± SD): 
WB BMD (g/cm2): 
0.880 ± 0.106 
Colombo et 
al. (2005) 
Italy 
Longitudinal 
study 
(4.6 years) 
11.9 ± 4.4 5 (60%) 17.0 ± 2.5 141.0 ± 22.6 37.9 ± 12.8 
Nontransplante
d patients with 
cystic fibrosis 
Hologic QDR 
2000 dual-energy 
x-ray 
absorptiometry 
scanner (Hologic 
Inc., Bedford, 
MA, USA). 
(Mean ± SD): 
WB BMD (g/cm2): 
0.854 ± 0.073 
(Mean ± SD): 
WB BMD (g/cm2): 
0.906 ± 0.078 
Hillman et al. 
(2008) 
USA 
Longitudinal 
study 
9.1 ± 2.3 9 (NR) 15.9 ± 1.1   134 ± 14 29.3 ± 7.5 
Patients with 
cystic fibrosis 
Hologic 1000W 
dual-energy x-
Changes 
(mean ± SD): 
 
(9 months) (pero es de 
todos los 
sujetos, ya 
que no 
muestran la 
edad sólo del 
grupo 
placebo) 
(igual que 
con la edad) 
(igual que 
con la edad) 
(igual que 
con la edad) 
ray 
absorptiometry 
scanner 
WB BMD (g/cm2): 
0.033 ± 0.027 
LS BMD (g/cm2): 
0.041 ± 0.045 
Schulze et al. 
(2006) 
USA 
Longitudinal 
study 
(1-4 years) 
12.1 ± 3.2 18 (0%) 18.0 ± 3.0 146 ± 15 39.6 ± 13.9 
Patients with 
cystic fibrosis 
Hologic QDR-
4500A dual-
energy x-ray 
absorptiometry 
scanner 
Z-score 
(mean ± SD): 
LS BMD: 
-0.40 ± 1.13 
Z-score 
(mean ± SD): 
LS BMD:  
-0.46 ± 0.94 
Sharma et al. 
(2017) 
New 
Zealand 
Longitudinal 
study 
(2 years) 
12.1 ± 2.0 40 (0%) 
Z-score:  
-0.17 ± 1.05 
Z-score:  
-0.49 ± 0.88 
Z-score:  
-0.36 ± 0.93 
Patients with 
cystic fibrosis 
Lunar Prodigy 
dual-energy x-
ray 
absorptiometry 
scanner (GE 
Health 
Care) 
Z-score 
(mean ± SD): 
LS BMD: 
-0.94 ± 0.88 
Z-score 
(mean ± SD): 
LS BMD: 
-1.13 ± 1.0 
Ujhelyi et al. 
(2004) 
Hungary 
Longitudinal 
study 
(2 years) 
8.3 (4 - 12) 11 (63.6%) NR 115.1 ± 9.1 19.5 ± 4.7 
Patients with 
cystic fibrosis 
Dual x-ray 
absorptiometry 
(Hologic QDR 
4500C, Hologic, 
Waltham, MA, 
U.S.A.) 
Changes 
(mean ± SD): 
LS BMD (g/cm2): 
0.04 ± 0.04 
FN BMD (g/cm2): 
0.08 ± 0.06 
 
 
Ujhelyi et al. 
(2004) 
Hungary 
Longitudinal 
study 
(2 years) 
 
14.9 (8 - 19) 
16 (56.3%) NR 149.0 ± 16.9 37.0 ± 11.8 
Patients with 
cystic fibrosis 
Dual x-ray 
absorptiometry 
(Hologic QDR 
4500C, Hologic, 
Waltham, MA, 
U.S.A.) 
Changes 
(mean ± SD): 
LS BMD (g/cm2): 
0.10 ± 0.07 
FN BMD (g/cm2): 
0.07 ± 0.07 
 
Not reported: NR 
 
Table 2. Characteristics of studies included in the systematic review and meta-analysis with healthy participants. 
Study (year) Country 
Study 
design 
Population characteristics (baseline) Outcome 
Age  
[years (mean 
± SD)] 
Sample size 
[n (% male)] 
BMI 
[kg/m2 (mean 
± SD)] 
Stature 
[cm (mean 
± SD)] 
Weight 
[kg (mean  
± SD)] 
Type of 
population  Method Baseline bone Follow-up bone 
Agostinete et 
al. (2016) 
Brazil 
A 9-mo 
follow-up 
11.9 ± 2.2 13 (100%)  NR 154.5 ± 13.1 NR 
Healthy male 
adolescents 
Lunar DPX-NT 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
1.001 ± 0.100 
LS BMD (g/cm2): 
0.857 ± 0.130 
Mean ± SD: 
WB BMD (g/cm2): 
1.041 ± 1.106 
LS BMD (g/cm2): 
0.901 ± 0.147 
Ara et al. 
(2006) 
Spain 
3.3-year 
follow-up 
period 
9.3 ± 1.6 16 (100%) 16.9 ± 2.2 136.5 ± 10.8 31.9 ± 7.6 
Healthy male 
children and 
adolescents 
Hologic QDR-
1500 dual-energy 
x-ray 
absorptiometry 
scanner 
Changes (mean ± 
SD): 
WB BMD (g/cm2): 
9.25 ± 4.34 
 
Bonjour et al. 
(1997) 
Switzerland 
48 wk 
follow-up 
7.9 ± 0.1 53 (0%) 16.6 ± 0.3 127.2 ± 0.8 26.9 ± 0.6 
Healthy 
prepubertal 
caucasian girls 
Hologic QDR-
2000 dual-energy 
x-ray 
absorptiometry 
scanner 
Mean ± SEM: 
LS BMD (g/cm2): 
0. 615 ± 0.008 
FN BMD (g/cm2): 
0. 622 ± 0.009 
Mean ± SEM: 
LS BMD (g/cm2): 
0. 638 ± 0.008 
FN BMD (g/cm2): 
0. 635 ± 0.009 
Cameron et 
al. (2004) 
Australia 
A 6-mo 
follow-up 
10.3 ± 1.5 51 (0%) NR 141.62 ± 9.45 37.5 ± 9.5 
Healthy 
australian 
Twins 
QDR 1000W 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
LS BMD (g/cm2): 
0.697 ± 0.085 
FN BMD (g/cm2): 
0.697 ± 0.084 
Mean ± SD: 
LS BMD (g/cm2): 
0.724 ± 0.097 
FN BMD (g/cm2): 
0.714 ± 0.615 
Cameron et 
al. (2004) 
Mismo 
estudio que el 
anterior 
Australia 
A 12-mo 
follow-up 
10.4 ± 1.5 48 (0%) NR 141.60 ± 9.52 37. ± 9.8 
Healthy 
australian 
Twins 
QDR 1000W 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
LS BMD (g/cm2): 
0.697 ± 0.085 
FN BMD (g/cm2): 
0.697 ± 0.084 
Mean ± SD: 
LS BMD (g/cm2): 
0.759 ± 0.114 
FN BMD (g/cm2): 
0.742 ± 0.107 
Cameron et 
al. (2004) 
Mismo 
estudio que el 
anterior 
Australia 
A 18-mo 
follow-up 
10.4 ± 1.5 42 (0%) NR 142.12 ± 9.18 37.6 ± 9.5 
Healthy 
australian 
Twins 
QDR 1000W 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
LS BMD (g/cm2): 
0.697 ± 0.085 
FN BMD (g/cm2): 
0.697 ± 0.084 
Mean ± SD: 
LS BMD (g/cm2): 
0.804 ± 0.129 
FN BMD (g/cm2): 
0.765 ± 0.112 
Cameron et 
al. (2004) 
Mismo 
estudio que el 
anterior 
Australia 
A 24-mo 
follow-up 
10.6 ± 1.5 24 (0%) NR 141.80 ± 9.12 37.1 ± 7.3 
Healthy 
australian 
Twins 
QDR 1000W 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
LS BMD (g/cm2): 
0.697 ± 0.085 
FN BMD (g/cm2): 
0.697 ± 0.084 
Mean ± SD: 
LS BMD (g/cm2): 
0.833 ± 0.142 
FN BMD (g/cm2): 
0.816 ± 0.131 
Chevalley et 
al. (2011) 
Switzerland 
A 12-y 
follow-up 
7.9 ± 0.5 124 (0%) 16.2 ± 1.8 127.7 ± 5.9 26.5 ± 4.1 Healthy girls 
Hologic QDR-
4500 dual-energy 
x-ray 
absorptiometry 
scanner 
Mean ± SD: 
FN BMD (g/cm2): 
0.634 ± 0.074 
Mean ± SD: 
FN BMD (g/cm2):  
(after 1 year) 
0.647 ± 0.075 
FN BMD (g/cm2):  
(after 2 years) 
0.675 ± 0.078 
FN BMD (g/cm2):  
(after 4 years) 
0.751 ± 0.103 
FN BMD (g/cm2):  
(after 8 years) 
0.867 ± 0.111 
FN BMD (g/cm2):  
(after 12 years) 
0.858 ± 0.108 
Erlandsson et 
al. (2012) 
Canada 
A 14-y 
follow-up 
11.9 ± 1.7 22 (0%) NR 151.6 ± 11.7 44.3 ± 11.9 
Healthy white 
girls 
Hologic 2000 
QDR dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.8 ± 0.1 
LS BMD (g/cm2): 
0.7 ± 0.2 
FN BMD (g/cm2): 
0.7 ± 0.1 
Mean ± SD: 
WB BMD (g/cm2): 
1.1 ± 0.1 
LS BMD (g/cm2): 
1.0 ± 0.1 
FN BMD (g/cm2): 
0.9 ± 0.6 
Fuchs et al. 
(2001) 
USA 
A 7-mo 
follow-up 
7.6 ± 0.2 
44 (59.09%) 
26 chicos y 
18 chicas 
NR 126.8 ± 1.2 NR 
Healthy school 
children 
Hologic 
QDR/4500-A 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SEM: 
LS BMD (g/cm2): 
0.550 ± 0.008  
FN BMD (g/cm2): 
0.613 ± 0.010 
Mean ± SEM: 
LS BMD (g/cm2): 
0.571 ± 0.008 
FN BMD (g/cm2): 
0.635 ± 0.009 
Gómez-
Brutón et al. 
(2017) 
Spain 
An 8-mo 
follow-up 
14.1 ± 2.3 
28 (57.14%) 
16 chicos y 
12 chicas 
20.4 ± 3.3 159.8 ± 11.7 52.8 ± 13.4 
Healthy 
Caucasian 
adolescents 
QDR 4500-
Explorer dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
(less head) 
0.889 ± 0.076 
LS BMD (g/cm2): 
0.861 ± 0.128 
FN BMD (g/cm2): 
0.833 ± 0.116 
Mean ± SD: 
WB BMD (g/cm2):  
(less head) 
0.905 ± 0.075 
LS BMD (g/cm2): 
0.886 ± 0.122 
FN BMD (g/cm2): 
0.844 ± 0.110 
Lambert et al. 
(2008) 
United 
Kingdom 
an 18-mo 
randomize
d 
controlled 
trial with 
2-y 
follow-up 
11.4 ± 0.5 44 (0%) 19.0 ± 3.1 149.8 ± 8.2 43.2 ± 10.1 
Healthy white 
girls 
QDR 4500A 
dual-energy x-
ray 
absorptiometry 
scanner 
 
Mean ± SD: 
WB BMD (g/cm2): 
0.88 ± 0.06 
LS BMD (g/cm2): 
0.70 ± 0.11 
Mean ± SD: 
WB BMD (g/cm2): 
0.954 ± 0.004 
LS BMD (g/cm2): 
0.831 ± 0.007 
Mackelvie et 
al. (2002) 
Canada 
A 7-
Month 
Randomiz
ed 
Controlle
d 
10.3 ± 0.7 60 (100%) 18.0 ± 4.0 141.8 ± 7.1 36.6 ± 10.1 
Healthy Asian 
and white  
children (North 
American or 
European 
origin) 
QDR 4500W 
dual-energy x-
ray 
absorptiometry 
scanner 
Changes (mean 
±95%CI): 
LS BMD (g/cm2): 
0.020 (0.015-
0.025)  
FN BMD (g/cm2): 
0.014 (0.009-
0.019) 
 
Markovic et 
al. (2005) 
USA 
4-y 
follow-up 
 
10.8 ± 0.7 123 (0%) NR 145.2 ± 7.0 40.2 ± 9.0 
Healthy 
Caucasian girls 
GE-Lunar DPX-
L dual-energy x-
ray 
absorptiometry 
scanner 
Changes (mean ± 
SD): 
WB BMD (g/cm2): 
0.204 ± 0.035 
 
 
Markovic et 
al. (2005) 
Mismo 
estudio que el 
anterior 
USA 
7-y folow-
up 
 
10.8 ± 0.7 100 (0%) NR 145.2 ± 7.0 40.2 ± 9.0 
Healthy 
Caucasian girls 
GE-Lunar DPX-
L dual-energy x-
ray 
absorptiometry 
scanner 
Changes (mean ± 
SD): 
WB BMD (g/cm2): 
0.263 ± 0.044 
 
Nickols et al. 
(1999) 
USA 
6-month 
follow-up 10.1 ± 0.3 9 (0%) NR 138.9 ± 2.4 30.3 ± 1.7 
Healthy 
premenarcheal 
girls 
QDR-1000 W 
dual-energy x-
ray 
Mean ± SEM: 
WB BMD (g/cm2): 
0.835 ± 0.012 
Mean ± SEM: 
WB BMD (g/cm2): 
0.845 ± 0.013 
Caucasian absorptiometry 
scanner 
LS BMD (g/cm2): 
0.620 ± 0.019  
FN BMD (g/cm2): 
0.647 ± 0.023 
LS BMD (g/cm2): 
0.6412± 0.020 
FN BMD (g/cm2): 
0.663 ± 0.024 
Nickols et al. 
(1999) 
Mismo 
estudio que el 
anterior 
USA 
12-month 
follow-up 10.1 ± 0.3 9 (0%) NR 138.9 ± 2.4 30.3 ± 1.7 
Healthy 
premenarcheal 
girls 
Caucasian 
QDR-1000 W 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SEM: 
WB BMD (g/cm2): 
0.835 ± 0.012  
LS BMD (g/cm2): 
0.6200± 0.019  
FN BMD (g/cm2): 
0.647 ± 0.023 
Mean ± SEM: 
WB BMD (g/cm2): 
0.864 ± 0.014 
LS BMD (g/cm2): 
0.666 ± 0.022 
FN BMD (g/cm2): 
0.675 ± 0.025 
Vaitkeviciute 
et al. (2016) 
Estonia 
12-month 
follow-up 
11.9 ± 0.6 
96 (100%) 20.5 ± 5.2 153.8 ± 7.4 49.3 ± 16.0 
Healthy school 
children 
Lunar DPX-IQ 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.983 ± 0.069 
LS BMD (g/cm2): 
0.831 ± 0.097 
FN BMD (g/cm2): 
0.895 ± 0.086 
Mean ± SD: 
WB BMD (g/cm2): 
1.018 ± 0.081 
LS BMD (g/cm2): 
0.890 ± 0.121 
FN BMD (g/cm2): 
0.940 ± 0.103 
Vaitkeviciute 
et al. (2016) 
Mismo 
estudio que el 
anterior 
Estonia 
24-month 
follow-up 
11.9 ± 0.6 
96 (100%) 20.5 ± 5.2 153.8 ± 7.4 49.3 ± 16.0 
Healthy school 
children 
Lunar DPX-IQ 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.983 ± 0.069 
LS BMD (g/cm2): 
0.831 ± 0.097 
FN BMD (g/cm2): 
0.895 ± 0.086 
Mean ± SD: 
WB BMD (g/cm2): 
1.018 ± 0.081 
LS BMD (g/cm2): 
0.890 ± 0.121 
FN BMD (g/cm2): 
0.940 ± 0.103 
Zouch et al. 
(2015) 
France 
A 3-Yr 
Longitudi
nal Study 
11.74 ± 0.64 23 (100%) 18.6 ± 2.9 152.0 ± 6.0 42.6 ± 8.3 
Healthy 
Caucasian 
boys 
Hologic 
WB Delphi  
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.902 ± 0.042 
LS BMD (g/cm2): 
0.679 ± 0.071 
FN BMD (g/cm2): 
0.753 ± 0.065 
Mean ± SD: 
WB BMD (g/cm2): 
1.010 ± 0.087 
LS BMD (g/cm2): 
0.843 ± 0.121 
FN BMD (g/cm2): 
0.840 ± 0.100 
Bradney et al. 
(1998) 
Australia/ 
USA 
8-month 
follow-up 10.3 ± 0.2 19 (100%) NR 142.2 ± 1.3 40.1 ± 1.6 
Healthy school 
children 
Lunar DPX-L 
dual-energy x-
ray 
Mean ± SEM: 
WB BMD (g/cm2): 
0.92 ± 0.01 
LS BMD (g/cm2): 
Changes per month 
(mean ± SEM): 
WB BMD (g/cm2): 
0.002 ± 0.001 
absorptiometry 
scanner 
0.77 ± 0.02 
 
LS BMD (g/cm2): 
0.002 ± 0.001 
Johannsen et 
al. (2003) 
USA 
12-week 
interventi
on 
randomize
d trial 
10.0 ± 5.1 26 (45.2%) NR 136.6 ± 30.7 39.3 ± 20.7 
Healthy 
children 
Hologic 4500A 
dual-energy x-
ray 
absorptiometry 
scanner 
Changes (mean ± 
SEM): 
LS BMD (g/cm2): 
0.009 ± 0.004 
FN BMD (g/cm2): 
0.001 ± 0.005 
 
Laing et al. 
(2005) 
USA 
A 24-
month 
quasi-
experimen
tal 
6.0 ± 1.49 78 (0%) 17.3 ± 2.88 119.0 ± 11.8 25.2 ± 7.6 
Healthy 
females  
 
Hologic QDR-
1000W dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.669 ± 0.06 
LS BMD (g/cm2): 
0.557 ± 0.07 
Mean ± SD: 
WB BMD (g/cm2): 
0.736 ± 0.07 
LS BMD (g/cm2): 
0.609 ± 0.08 
Linden et al. 
(2006) 
Sweden 
2-year 
prospectiv
e 
controlled 
exercise 
interventi
on trial 
7.9 ± 0.6 50 (0%) NR 129.1 ± 7.9 27.4 ± 5.5 
Healthy 
elementary 
schools in a 
middle-class 
area 
Lunar DPX-L 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.84 ± 0.05 
LS BMD (g/cm2): 
0.70 ± 0.08 
FN BMD (g/cm2): 
0.71 ± 0.10 
 
Changes per year 
(mean ± SD): 
WB BMD (g/cm2): 
0.024 ± 0.009  
LS BMD (g/cm2): 
0.026 ± 0.015  
FN BMD (g/cm2): 
0.040 ± 0.040  
 
MacKelvie et 
al.(2001) 
 
Canada 
7-month 
randomize
d, 
prospectiv
e, school-
based 
interventi
on 
Prepubertal: 
10.1 ± 0.5 
 
Early  
pubertal: 
10.5 ± 0.6 
Prepubertal: 
26 (0%) 
 
Early 
pubertal: 
64 (0%) 
NR 
Prepubertal: 
137.3 ± 6.2 
 
Early 
pubertal: 
145.6 ± 6.4 
Prepubertal: 
31.1 ± 5.6 
 
Early 
pubertal: 
41.3 ± 8.3 
Healthy Asian 
and white  
children (North 
American or 
European 
origin) 
Hologic QDR 
4500 W dual-
energy x-ray 
absorptiometry 
scanner 
Prepubertal (mean 
± SD): 
WB BMD (g/cm2): 
0.860 ± 0.040 
LS BMD (g/cm2): 
0.630 ± 0.060 
FN BMD (g/cm2): 
0.630 ± 0.070 
 
Early pubertal 
(mean ± SD): 
WB BMD (g/cm2): 
Prepubertal 
changes (mean ± 
95%CI): 
WB BMD (g/cm2): 
0.017 (0.011-
0.023)  
LS BMD (g/cm2): 
0.027 (0.019-
0.034)  
FN BMD (g/cm2): 
0.024 (0.016-
0.031)  
0.870 ± 0.070 
LS BMD (g/cm2): 
0.690 ± 0.100 
FN BMD (g/cm2): 
0.670 ± 0.090 
 
 
Early pubertal 
(mean ± SD): 
WB BMD (g/cm2): 
0.030 (0.025-
0.035) 
LS BMD (g/cm2): 
0.044 (0.038-
0.049) 
FN BMD (g/cm2): 
0.034 (0.028-
0.039) 
McKay et al. 
(2000) 
 
Canada 
A 8 
months 
randomize
d school-
based 
exercise 
interventi
on study 
6.9 to 
10.2 years 
81 (NR) NR 133.9 ± 0.7 30.5 ± 0.8 
Healthy Asian 
and white  
children (North 
American or 
European 
origin) 
Hologic QDR 
4500 W dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SEM: 
WB BMD (g/cm2): 
0.807 ± 0.006 
LS BMD (g/cm2): 
0.581 ± 0.007 
FN BMD (g/cm2): 
0.642 ± 0.008 
Mean ± SEM: 
WB BMD (g/cm2): 
0.818 ± 0.006 
LS BMD (g/cm2): 
0.592 ± 0.007 
FN BMD (g/cm2): 
0.661 ± 0.009 
Moriss et al. 
(1997) 
Australia 
Prospectiv
e Ten-
Month 
Exercise 
Interventi
on 
9.5 ± 0.9 38 (0%) NR 138.6 ± 6.4 34.8 ± 5.2 
Healthy school 
girls 
Hologic QDR-
2000+ dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SEM: 
WB BMD (g/cm2): 
0.810 ± 0.01  
LS BMD (g/cm2): 
0.637 ± 0.01 
FN BMD (g/cm2): 
0.690 ± 0.07 
Changes (mean± 
SEM): 
WB BMD (g/cm2): 
0.010 ± 0.01 
LS BMD (g/cm2): 
0.008 ± 0.05 
FN BMD (g/cm2): 
0.012 ± 0.03 
Nichols et al. 
(2001) 
USA 
15 months 
follow-up 15.7 ± 0.1 11 (0%) NR 158.2 ± 3.1 63.8 ± 5.2 
Healthy 
females 
Lunar DPX dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
1.111 ± 0.066 
LS BMD (g/cm2): 
1.158 ± 0.135 
FN BMD (g/cm2): 
Mean ± SD: 
WB BMD (g/cm2): 
1.129 ± 0.065 
LS BMD (g/cm2): 
1.190 ± 0.125 
FN BMD (g/cm2): 
1.034 ± 0.086 1.048 ± 0.075 
Van 
Langendonck 
et al. (2003) 
Belgium 
9 months 
follow-up 8.7 ± 0.7 21 (0%) NR 132.22 ± 6.37 28.8 ± 4.5 
Healthy female 
twins 
Hologic QDR-
4500A dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.850 ± 0.030 
LS BMD (g/cm2): 
0.850 ± 0.030 
FN BMD (g/cm2): 
0.630 ± 0.060 
Changes (mean± 
SD): 
WB BMD (g/cm2): 
0.020 ± 0.020 
LS BMD (g/cm2): 
0.010 ± 0.020 
FN BMD (g/cm2): 
0.020 ± 0.020 
Chevalley et 
al. (2011) 
Switzerland 
an 8-yr 
cohort 
study 
7.4 ± 0.4 89 (100%) 15.9 ± 2.0 125.5 ± 6.2 25.2 ± 5.0 
Healthy 
prepubertal 
Caucasian boys 
Hologic QDR 
4500 dual-energy 
x-ray 
absorptiometry 
scanner 
Mean ± SD: 
LS BMD (g/cm2): 
0.568 ± 0.052 
FN BMD (g/cm2): 
0.688 ± 0.070 
Mean ± SD: 
LS BMD (g/cm2): 
0.918 ± 0.135 
FN BMD (g/cm2): 
0.901 ± 0.133 
Gustavsson et 
al. (2003) 
Sweden 
3 years 
follow-up 16.1 ± 0.6 24 (100%) NR 179.0 ± 6.0 69.2 ± 10.1 
Healthy 
Caucasian boys 
Lunar DPX-L 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
1.15 ± 0.11 
LS BMD (g/cm2): 
1.10 ± 0.14 
FN BMD (g/cm2): 
1.13 ± 0.15 
Mean ± SD: 
WB BMD (g/cm2): 
1.26 ± 0.09 
LS BMD (g/cm2): 
1.24 ± 0.14 
FN BMD (g/cm2): 
1.21 ± 0.16 
Katzman et 
al. (1991) 
USA 
2 years 
follow-up 14.3 ± 3.6 45 (0%) 20.0 ± 2.9 158.0 ± 13.2 50.6 ± 12.7 
Healthy 
adolescent 
females 
Hologic QDR 
1000W dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.904 ± 0.130 
LS BMD (g/cm2): 
1.009 ± 0.155 
Mean ± SD: 
WB BMD (g/cm2): 
0.993 ± 0.114 
LS BMD (g/cm2): 
1.005 ± 0.142 
Maggio et al. 
(2012) 
Switzerland 
9 month 
follow-up 10.5 ± 3.0 17 (47%) 17.8 ± 2.9 143.1 ± 19.1 38.3 ± 15.7 
Healthy 
children 
GE Lunar 
Prodigyi dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.94 ± 0.13 
LS BMD (g/cm2): 
0.83 ± 0.25 
FN BMD (g/cm2): 
0.86 ± 0.17 
Changes (mean± 
SD): 
WB BMD (g/cm2): 
0.020 ± 0.007 
LS BMD (g/cm2): 
0.033 ± 0.014 
FN BMD (g/cm2): 
0.025 ± 0.019 
Mølgaard et 
al. (2010) 
Denmark 
12 month 
follow-up 11.4 ± 0.2 74 (0%) NR 150.1 ± 6.9 40.5 ± 7.9 
Healthy Danish 
Caucasian girls 
Hologic 1000/W 
dual-energy x-
ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.863 ± 0.064  
LS BMD (g/cm2): 
0.697 ± 0.102 
Mean ± SD: 
WB BMD (g/cm2): 
0.909 ± 0.075 
LS BMD (g/cm2): 
0.788 ± 0.121 
Nogueira et 
al. (2015) 
Australia 
A 9-
month, 
cluster-
controlled 
trial 
10.7 ± 0.6 68 (100%) NR 143.7 ± 6.2 39.6 ± 9.2 
Healthy school 
children 
Norland Medical 
XR800 dual-
energy x-ray 
absorptiometry 
scanner 
Mean ± SD: 
WB BMD (g/cm2): 
0.765 ± 0.083 
LS BMD (g/cm2): 
0.674 ± 0.123 
FN BMD (g/cm2): 
0.803 ± 0.116 
Mean ± SD: 
WB BMD (g/cm2): 
0.806 ± 0.103 
LS BMD (g/cm2): 
0.705 ± 0.150 
FN BMD (g/cm2): 
0.843 ± 0.134 
NR: not reported 
 
 
 
 
..
CYSTIC FIBROSIS CHILDREN
Bhudhikanok et al 1998 (F)
Bhudhikanok et al 1998 (M)
Colombo et al 2004 (NT)
Colombo et al 2004 (T)
Hillman et al 2008
Subtotal  (I-squared = 0.0%, p = 0.829)
HEALTHY CHILDREN
Agostinete et al 2016
Ara et al 2006
Erlandsson et al 2012
Gustavsson et al 2003
Gómez-Brutón et al 2017
Katzman et al 1991
Laing et al 2005
Lambert et al 2008
Linden et al 2006
Mackelvie et al 2002 (Early)
Mackelvie et al 2002 (Pre)
Maggio et al 2012
Markovic et al 2005
Mølgaard et al 2010
Nickols et al 1999
Vaitkeviciute et al 2016
Zouch et al 2015
Subtotal  (I-squared = 35.8%, p = 0.071)
References
0.10 (-0.74, 0.94)
0.09 (-0.84, 1.01)
0.69 (-0.32, 1.70)
0.61 (-0.46, 1.68)
0.02 (-1.28, 1.33)
0.29 (-0.15, 0.74)
0.05 (-0.72, 0.82)
0.53 (0.01, 1.06)
0.41 (-0.18, 1.01)
0.23 (-0.34, 0.80)
0.21 (-0.31, 0.73)
0.73 (0.30, 1.15)
0.00 (-0.34, 0.34)
0.27 (-0.15, 0.69)
0.03 (-0.25, 0.30)
0.19 (-0.06, 0.44)
0.17 (-0.22, 0.55)
0.69 (0.16, 1.22)
0.06 (-0.14, 0.26)
0.66 (0.33, 0.99)
0.29 (-0.64, 1.22)
0.05 (-0.24, 0.33)
0.34 (-0.25, 0.92)
0.25 (0.13, 0.37)
SMD (95% CI)
28.19
23.25
19.50
17.38
11.68
100.00
2.16
4.09
3.35
3.59
4.15
5.59
7.45
5.68
9.37
10.24
6.38
4.03
12.17
7.72
1.54
9.05
3.44
100.00
Weight
%
  0-1.3 -1 -.7 -.4 .2 .5 .8 1.1 1.4 1.7 2
..
CYSTIC FIBROSIS CHILDREN
Bhudhikanok et al 1998 (F)
Bhudhikanok et al 1998 (M)
Hillman et al 2008
Schulze et al 2006
Sharma et al 2017
Ujhelyi et al 2004 (A)
Ujhelyi et al 2004 (C)
Subtotal  (I-squared = 0.0%, p = 1.000)
HEALTHY CHILDREN
Bonjour et al 1997
Cameron et al 2004
Erlandsson et al 2012
Fuchs et al 2001
Gustavsson et al 2003
Gómez-Brutón et al 2017
Johannsen et al 2003
Katzman et al 1991
Lambert et al 2008
Linden et al 2006
Mackelvie et al 2002 (Early)
Mackelvie et al 2002 (Pre)
Maggio et al 2012
Mølgaard et al 2010
Nickols et al 1999
Vaitkeviciute et al 2016
Zouch et al 2015
Subtotal  (I-squared = 21.0%, p = 0.209)
References
0.12 (-0.71, 0.96)
0.13 (-0.79, 1.06)
0.03 (-1.28, 1.33)
0.06 (-0.60, 0.71)
0.20 (-0.24, 0.64)
0.05 (-0.93, 1.03)
0.02 (-1.16, 1.21)
0.13 (-0.16, 0.41)
0.40 (0.01, 0.78)
0.30 (-0.09, 0.69)
0.41 (-0.18, 1.01)
0.40 (-0.02, 0.82)
0.21 (-0.36, 0.78)
0.25 (-0.28, 0.77)
0.44 (0.04, 0.84)
-0.03 (-0.44, 0.39)
0.26 (-0.16, 0.68)
0.02 (-0.26, 0.30)
0.28 (0.03, 0.53)
0.27 (-0.13, 0.66)
0.57 (0.06, 1.08)
0.81 (0.48, 1.15)
0.38 (-0.55, 1.31)
0.06 (-0.23, 0.34)
0.22 (-0.36, 0.80)
0.29 (0.18, 0.40)
SMD (95% CI)
11.53
9.40
4.72
18.74
41.52
8.37
5.72
100.00
6.40
6.27
3.07
5.57
3.32
3.83
6.02
5.68
5.57
10.11
11.65
6.15
4.03
7.89
1.34
9.88
3.21
100.00
Weight
%
  0-1.3 -1 -.7 -.4 .2 .5 .8 1.1 1.4 1.7 2
..
CYSTIC FIBROSIS CHILDREN
Bhudhikanok et al 1998 (F)
Bhudhikanok et al 1998 (M)
Ujhelyi et al 2004 (A)
Ujhelyi et al 2004 (C)
Subtotal  (I-squared = 0.0%, p = 0.999)
HEALTHY CHILDREN
Bonjour et al 1997
Cameron et al 2004
Chevalley et al 2011
Erlandsson et al 2012
Fuchs et al 2001
Gustavsson et al 2003
Gómez-Brutón et al 2017
Johannsen et al 2003
Linden et al 2006
Mackelvie et al 2002 (Early)
Mackelvie et al 2002 (Pre)
Maggio et al 2012
Nickols et al 1999
Vaitkeviciute et al 2016
Zouch et al 2015
Subtotal  (I-squared = 0.0%, p = 0.558)
References
0.13 (-0.71, 0.96)
0.11 (-0.82, 1.03)
0.04 (-0.95, 1.02)
0.05 (-1.13, 1.23)
0.09 (-0.39, 0.57)
0.20 (-0.18, 0.58)
0.04 (-0.35, 0.43)
0.54 (0.29, 0.79)
0.10 (-0.49, 0.69)
0.35 (-0.07, 0.77)
0.11 (-0.46, 0.67)
0.12 (-0.41, 0.64)
0.04 (-0.35, 0.42)
0.01 (-0.27, 0.29)
0.21 (-0.04, 0.46)
0.24 (-0.15, 0.63)
0.32 (-0.17, 0.81)
0.22 (-0.70, 1.15)
0.05 (-0.23, 0.33)
0.35 (-0.23, 0.93)
0.20 (0.11, 0.30)
SMD (95% CI)
32.96
26.86
23.68
16.50
100.00
6.42
6.09
14.82
2.66
5.25
2.90
3.36
6.25
11.82
14.82
6.09
3.86
1.08
11.82
2.75
100.00
Weight
%
  0-1.3 -1 -.7 -.4 .2 .5 .8 1.1 1.4 1.7 2
